# BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.**

STIC-ILL

5/14

**From:** Canella, Karen
**Sent:** Wednesday, May 14, 2003 3:05 PM
**To:** STIC-ILL
**Subject:** ill order 09/230,955

4457746

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/230,955

1. American Journal of Pathology:
   1993 Feb, 142(2):403-412
   1993, 143(4):1150-1158
   1984, 114(3):454-460
   1996, 148(3):865-875
   1965 Sep, Vol. 44, pp. 280-282

COMPLETED

2. Cancer Research, 1993 May 15, 53(10 suppl):2287-2299

3. Cancer epidemiology, biomarkers and Prevention, 1996 Jul, 5(7):549-557

4. Lab Investigation:
   1980, 42(1):91-96
   1988, 58(2):141-149

5. Gynecol Oncol, 1982, 13(1):58-66

6. International Journal of Gynecological Pathology:
   1985, 4(4):300-313
   1986, 5(2):151-162
   1992, 11(1):24-29

7. Differentiation:
   1986, 31(3):191-205
   1988, 39(3):185-196

10853045

8. Cancer (Phila), 1989, 63(7):1337-1342

9. Cancer Res, 1990, 50(16):5143-5152

10. Virchows Arch B Cell Pathol Incl Mol Pathol, 1987, 54 (2):98-110

11. Acta Histochemica et Cytochemica:
    1994, 27(3):251-257
    1996, 29(1):51-56

12. Archives of Gynecology and Obstetrics, 1989, 246(4):233-242

13. Clin Lab Med, 1995 Sep, 15(3):727-742

14. Clin Obstet Gynaecol, 1984 Apr, 11 (1):5-23

 0272–2712/95 $0.00 + .20

# IMMUNOHISTOCHEMICAL APPROACHES TO DIAGNOSIS IN GYNECOLOGIC PATHOLOGY

Jay H. Beckstead, MD

Immunohistochemical techniques have become widely used in many areas of surgical pathology in recent years. These procedures can provide practical diagnostic information in many areas including gynecologic pathology. The following discussion is organized into sections by major anatomic areas of gynecologic interest. Within each section, specific pathologic questions approachable by immunohistochemical studies are discussed. The scope of this review is limited to relatively practical questions that may be encountered by a practicing pathologist and to commercially available antibodies applicable to paraffin-embedded tissue sections. Given the above parameters, a description of the reagents that may be applicable to the question is presented. This is not intended to imply that all of the reagents need to be applied in each case. Often a single, carefully selected pair of antibodies is completely sufficient to answer the pathologic question. In general, the use of antibodies in pairs serves as an important control in diagnostic interpretation.

## VULVA

### Paget's Disease Versus Melanoma

This is a relatively straightforward diagnostic problem by immunohistochemical techniques. The malignant epithelial cells of Paget's dis-

From the Department of Pathology, Oregon Health Sciences University, Portland, Oregon

ease express the keratins of simple epithelium (Ker 7, 8, 18, 19).[52] Because the normal vulvar epithelium is similar to the skin expressing Ker 1, 5, 10, and 14,[53, 54] staining with an antibody to low-molecular weight keratins such as CAM 5.2 (Ker 8, 18, 19) will reveal the Paget's cells in stark contrast to the surrounding negative epidermis (Fig. 1). The same cells will often be positive with antibodies to tumor-associated proteins, including carcinoembryonic antigen (CEA) and the tumor-associated glycoprotein-72 (B72.3), and negative with the antigens commonly expressed by melanomas, S-100 protein, and the melanoma-specific antigen HMB-45.[59] Melanomas typically are positive with both S-100 and HMB-45 but lack cytokeratin. However, some melanomas may show reactions with low-molecular weight keratins.[49]

## Classification of Vulvar Intraepithelial Neoplasia

Classification of vulvar intraepithelial neoplasia (VIN) is based primarily on morphologic examination, although there are changes in the patterns of keratin expression in this tissue with dysplasia as determined by immunohistochemistry that may be a useful adjunct to diagnosis. The typical keratins expressed in the vulva are 1, 5, 10, and 14[53, 54]; however, these shift dramatically in VIN.[21] Staining with the antibody AE1 (Ker 10, 13, 14, and 19) is confined to the basal layer of the normal



**Figure 1.** A biopsy of the vulva showing Paget's disease. The malignant cells are strongly labeled by the antibody CAM 5.2, which stains low molecular weight keratins. The surrounding epidermis is negative.

vulvar epithelium; however, in VIN 1 and 2, AE1 staining becomes expressed in the mature layers of epithelium. In VIN 3, AE1 is expressed throughout the epithelium. Warty and basaloid VIN 3 show some differences in the expression of keratins that may be useful in confirming the separation of these two lesions. Warty VIN 3 shows a patchy distribution of AE2 (Ker 1, 2, and 10), whereas basaloid VIN 3 is negative. The low molecular weight keratins, detected by CAM 5.2, are expressed focally in basaloid VIN 3, but not in other forms of VIN or in squamous carcinomas of the vulva.

### Separation of Verrucous and Well-Differentiated Squamous Carcinoma

Verrucous carcinomas of the vulva rarely metastasize and should be differentiated from well-differentiated squamous carcinomas at this site. The pattern of keratin distribution with the broad spectrum keratin cocktail AE1/AE3 (Ker 1–8, 10, 13–16, 19) can provide additional data that may be useful in confirming the initial morphologic impression, particularly in biopsy material. Verrucous carcinomas typically show a uniform distribution of AE1/3 throughout the lesion, whereas squamous carcinomas show a patchy distribution of these keratins.[7]

### Prognosis in Squamous Carcinoma of the Vulva

Although the use of specific antigenic determinants as prognostic and therapeutic markers is a relatively recent phenomenon, it is likely that its use will increase as clinicopathologic correlations are established. Expression of keratin 10 may have prognostic value in squamous carcinoma of the vulva. Ivanyi and colleagues[32] found that squamous carcinomas expressing keratin 10 did not recur; lesions that did not express the antigen frequently recurred.

## CERVIX

### Cervical Intraepithelial Neoplasia and Squamous Carcinoma

The grading of cervical intraepithelial neoplasia (CIN) and its separation from invasive squamous carcinoma can often be difficult. Immunohistochemistry can provide some additional data that may sometimes be valuable. CIN shows a keratin pattern similar to that of immature squamous metaplasia with expression of keratins 5, 13, 14, and 17.[27, 33, 70–72] The keratins labeled by CAM 5.2 (Ker 8, 18, 19) are thus usually absent from CIN 1 and 2, and are very infrequently detected in CIN 3; however, they are strongly expressed by invasive squamous CA (Fig.

2).[64] Many different keratins have been reported with invasive cervical squamous carcinomas.[54, 71] However, some authors have noted distinctions between keratinizing carcinomas that usually express keratins 4, 10, and 17 while the same proteins are very infrequently present in nonkeratinizing carcinomas.[33]

There have been several studies that have suggested some diagnostic or prognostic use for CEA in squamous lesions of the cervix, although these remain somewhat controversial. CEA may be positive in squamous metaplasia and CIN I, although the normal squamous cells of the cervix are negative. One study found that the presence of keratin 8 and CEA was associated with a more aggressive clinical course.[16] CIN 3 and invasive squamous cell carcinoma are usually positive with CEA (Fig. 3),[46] but CEA positively has not proven to be valuable in predicting progression of CIN.[43] Estrogen (ER) and progesterone receptors (PR) (PR more frequently) may be expressed in squamous carcinomas of the cervix, but appear to have no prognostic or therapeutic significance.[17, 38, 44, 57, 69] Receptor positivity, however, may be useful in confirming a cervical origin for a squamous carcinoma.

## Identification of Early Invasion

Although morphologic recognition of invasion is generally sufficient for diagnosis, immunohistochemistry can provide supportive informa-

**Figure 2.** A biopsy of the cervix showing normal cervical epithelium overlying an invasive squamous carcinoma. The malignant cells are labeled strongly by the antibody CAM 5.2. The normal mucosa shows only basal layer staining.



**Figure 3.** A cervical biopsy showing CIN III. The abnormal squamous cells are strongly positive with antibody to CEA, whereas the adjacent endocervical cells are negative.

tion in difficult cases. Any broad-spectrum keratin can aid in the identification of infiltrating tumor cells and, as noted above, there is a consistent switch to the expression of keratins 8 and 18 with invasion. Another change is the induction of smooth muscle actin in the stromal cells at the site of invasion.[11] Changes in the basement membrane (laminin and collagen type IV)[20] have not proven to be of significant practical value in the diagnosis of early invasion because of the ability of many invasive tumors to produce basement membrane.

## ENDOCERVIX

### Diagnosis of Endocervical Adenocarcinoma

Adenocarcinomas of the endocervix show the typical keratin profile of a simple epithelium (Ker 7, 8, 18, 19).[54] Small amounts of keratins 4, 14, and 17 have also been observed.[33, 54, 71] These lesions do not express keratins 5 and 6, which are commonly expressed in squamous carcinomas of the cervix. These phenotypic differences may be useful in separating poorly differentiated adenocarcinomas from squamous carcinomas.

Endocervical adenocarcinomas often can be difficult to separate from endometrial adenocarcinomas by morphologic criteria, particularly in biopsy specimens. There are, however, some immunohistochemical marker differences that may assist in this differential diagnosis. Tumors

of endocervical origin commonly are vimentin-negative and CEA-positive (Fig. 4*A*), while those of endometrial origin are vimentin-positive and CEA-negative (Fig. 4*B*).[15, 56]

## ENDOMETRIUM

### Diagnosis of Endometrial Adenocarcinoma

As noted above, carcinomas of endometrial origin commonly coexpress vimentin and keratins,[48, 63] typically keratins 7, 8, 18, and 19[13, 54] and lesser amounts of the stratification-related keratins 5, 6, 10, 11, 13, 14, 16, and 17.[56] Stratification-related proteins are rarely expressed in adenocarcinomas of the gastrointestinal (GI) tract, kidney, or breast. This may be a useful differential consideration when tumors from these sources must be ruled out. The presence of keratin 7 can also be of some differential importance because it is seldom present in tumors of the lower GI tract.[65] Scattered cells positive with antibodies against glial fibrillary acidic protein (GFAP) have been reported in both endometrial and ovarian adenocarcinomas.[56] Because expression of these proteins is extremely rare outside the nervous system, this may serve as a clue to a gynecologic origin.

### Prognosis in Endometrial Carcinoma

ER and PR status, particularly PR, demonstrates a good correlation with level of differentiation, prognosis, and response to hormonal therapy in endometrial adenocarcinomas,[5, 9, 10, 26, 36] but the use of these data has not been widespread. Discordant data from metastatic and primary sites suggest that multiple sites should be tested for effective results.[68]

### Diagnosis of Endometrial Stromal Sarcoma

Endometrial stromal sarcomas may occasionally be difficult to separate from anaplastic carcinomas by morphologic criteria alone. Immunohistochemistry may be helpful in this differential. These mesenchymal tumors typically show strong vimentin positivity and very little keratin, in contrast to carcinomas,[40] although it is clear that small amounts of low-molecular weight keratins may be expressed by scattered tumor cells in these malignancies.[22, 25] Although both the normal endometrial stroma and stromal sarcomas express markers of muscle differentiation (muscle specific actin, smooth muscle actin, desmin), staining is usually focal.[25]

Low-grade endometrial stromal sarcomas often express the ER, but this is rare in high-grade tumors.[60, 75] The presence of ERs has some value in predicting a response to therapeutic hormonal manipulation.

**Figure 4.** with an ar adjacent s to an endo ated endo cinoma an



**Figure 4.** *A*, Section from a moderately differentiated endocervical adenocarcinoma stained with an antibody to vimentin. The adenocarcinoma is completely negative whereas the adjacent stroma show strong labeling. Compare this result with the same marker applied to an endometrial adenocarcinoma in *B*, which shows a section from a moderately differentiated endometrial adenocarcinoma stained with an antibody to vimentin. Both the adenocarcinoma and the adjacent stroma show strong labeling.

### Diagnosis of Mixed Mesodermal Tumors

Malignant mixed mesodermal tumors are complex tumors that may show a variety of differentiation pathways. Although these have been traditionally approached morphologically, immunohistochemistry may aid in recognition of the specific mesenchymal elements such as leiomyosarcoma or rhabdomyosarcoma in these tumors.[2, 4, 63, 66, 67]

## UTERUS

### Diagnosis of Smooth Muscle Tumors

Analysis of intermediate filament proteins is rarely necessary in the diagnosis of smooth muscle tumors in the uterus. In some cases, confirmation of smooth muscle origin with antibodies to desmin or smooth muscle actin may be useful.[3] Importantly, occasional cells in these neoplasms may express low-molecular weight keratins.[8, 28, 62]

## FALLOPIAN TUBE AND OVARY

### Diagnosis and Classification of Ovarian Adenocarcinoma

Tumors derived from the surface epithelium of the ovary generally express simple epithelial keratins (keratin 7, 8, and 19).[54, 58, 63, 78] Endometrioid carcinomas differ from serous tumors in their expression of keratins 4, 5, and 13,[56] an indication of the potential for squamous differentiation. Most ovarian adenocarcinomas coexpress vimentin with keratin.[48, 56, 63] The major exceptions to this rule are mucinous tumors and Brenner tumors.[78]

Serous ovarian tumors are among the relatively small group of epithelial malignancies that may express the S-100 protein (tumors of breast and salivary gland origin are the other common ones).[42] Although CEA is often positive in mucinous tumors and may be seen in serous, endometrioid, and clear cell tumors, the patchy focal nature of the staining contrasts with the strong diffuse staining typical of gastrointestinal carcinomas.[23, 29]

Small amounts of alpha-fetoprotein (AFP) are relatively common in ovarian embryonal carcinomas and endodermal sinus tumors. This positivity usually appears as scattered cells or clusters of cells. This may be of help in separating endodermal sinus tumors from clear cell adenocarcinomas, which generally lack AFP. In addition, clear cell carcinomas often express the hematopoietic marker CD15, which is rare in yolk sac tumors.[80]

Ovarian hepatoid carcinomas are AFP-positive.[31] AFP is also occasionally reported in other tumors of gynecologic origin.[37, 45]

## Separation of Gynecologic Adenocarcinomas from Other Adenocarcinomas

Although separation of adenocarcinomas of other sites from tumors of gynecologic origin may be of significant clinical value, it is often impossible on morphologic grounds. Immunohistochemical reactions can provide significant help in this regard. Adenocarcinomas of the endometrium and ovary are negative with cytokeratin 20, with the exception of some mucinous carcinomas of the ovary. This keratin is commonly expressed in adenocarcinomas of colonic, pancreatic, gastric, and biliary tract origin.[55] Thus, positivity with this marker suggests that a gynecologic primary is much less likely. Another useful marker is HAM56, a macrophage marker that stains many adenocarcinomas except those arising in the digestive tract.[24, 79] Most ovarian and endometrial carcinomas are positive (Fig. 5), which serves as a useful differential point. Staining with keratin 7 is typical of ovarian adenocarcinoma, but is very uncommon in the GI tract.[65]

Placental alkaline phosphatase (PLAP) is often noted in gynecologic carcinomas, including tumors of cervical, endocervical, endometrial (Fig. 6), and ovarian origin.[18] However, it is not commonly expressed by other tumors, with the exception of those of germ cell origin.

CA-125 is an oncofetal antigen commonly expressed in tumors of gynecologic origin, particularly those of ovarian, endometrial, and



**Figure 5.** A section from a moderately differentiated endometrial adenocarcinoma stained with the antibody HAM 56. The adenocarcinoma shows strong labeling on the apical surface of the malignant glands.



**Figure 6.** A section from a poorly differentiated ovarian adenocarcinoma stained with antibody to PLAP. The adenocarcinoma shows patchy but definite labeling on the malignant glands.

endocervical origin. It is most frequently positive in serous tumors of the ovary (Fig. 7). Unfortunately, it can also be expressed by adenocarcinomas of other origins. In addition, it can be expressed by hyperplastic cells,[61] further limiting its diagnostic usefulness. In patients whose serum CA-125 levels were not assessed in a timely manner, demonstration of the protein immunohistochemically in a tumor may be important to determine the value of serum levels in follow-up.

B72.3 is a monoclonal antibody to a tumor associated glycoprotein, although it is occasionally expressed in benign cells.[74] Adenocarcinomas of endocervical, endometrial, and ovarian origin are commonly positive with this marker as are adenocarcinomas of the GI tract and lung. B72.3 has been particularly useful in the evaluation of peritoneal cytology specimens because it is negative in mesothelial cells.[73]

The presence of nuclear staining with the estrogen receptor is a strong predictor of gynecologic or breast origin because the only other tumors commonly positive for this marker are those of the thyroid.[19]

## Sex Cord-Stromal Tumors

The transitional cell nests of Brenner tumor express keratins 10 and 11[41] and are negative with vimetin.[78] Brenner tumors are the only sex cord-stromal tumors that often express CEA.[34] Granulosa cell tumors are



**Figure 7.** A section from a serous ovarian adenocarcinoma reacted with an antibody against CA-125. The tumor cells show strong labeling of their apical surfaces.

vimentin-positive, but generally fail to express keratin in fixed tissue.[50, 51] Epithelial membrane antigen (EMA) is also negative.[12] The absence of keratin may occasionally be useful in separating a granulosa cell tumor from a poorly differentiated carcinoma. In granulosa-theca cell tumors, the thecal component expresses both keratin and vimentin.[77] In sex cord-stromal tumors, vimentin is expressed, although small amounts of keratin may also be seen.[77] Thecoma-fibroma tumors do not express smooth muscle actin, which may be useful for separating them from the rare ovarian leiomyomas.[14] Leydig cell tumors express vimentin as their only intermediate filament protein.[51]

## Diagnosis of Germ Cell Tumors

Although limited studies on ovarian germ cell tumors have been reported, the results show a general concordance with similar tumors in males. Dysgerminomas generally do not express keratin, whereas embryonal carcinomas, endodermal sinus tumors, and choriocarcinomas usually express the keratins of simple epithelia.[50, 51] Human chorionic gonadotropin (hCG) can be identified in trophoblastic cells in many germ cell tumors,[30] although it is usually not of diagnostic significance. PLAP is commonly expressed in germ cell tumors and may be useful in a differential diagnosis; however, it should be remembered that it can also be present in other carcinomas, particularly those of gynecologic origin.[18, 47]

## PLACENTA

### Separation of Decidual Cells from Trophoblasts

All trophoblastic cells express the keratins of simple epithelium (keratins 8, 18, and 19), whereas decidual cells, despite their epithelial-like appearance, do not.[35] The trophoblastic cells in hydatidiform moles demonstrate the same pattern of keratin expression.[51] Trophoblasts are also positive with human placental lactogen (hPL).[6] Placental site trophoblastic tumors are generally diffusely positive for keratin and hPL, with focal positivity with hCG. These same markers may occasionally be useful in the identification of trophoblasts to rule out an ectopic pregnancy.

### Diagnosis of Complete Mole

Human chorionic gonadotropin can be helpful in separating partial mole that expresses hCG moderately early in gestation but shows only weak positivity after 13 to 14 weeks. This contrasts with the strong expression observed in complete moles regardless of gestational age.[6] Another marker useful in separating partial from complete mole is hPL, which is strongly positive in partial mole but only weakly positive in complete mole.[6, 39] PLAP may also be useful, as it becomes increasingly positive with gestational age in partial moles, but is only weakly expressed in complete mole.[6]

### Confirmation of Small Cell Carcinoma

Small cell carcinomas with "neuroendocrine" features can occur in the cervix, endometrium, or ovary. In some situations, it may be useful to confirm this morphologic impression by demonstrating positivity with a neuroendocrine marker.[1, 76]

### References

1. Ambros RA, Park JS, Shah KV, et al: Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18 [published erratum appears in Mod Pathol 5:40, 1992]. Mod Pathol 4:586–593, 1991
2. Auerbach HE, LiVolsi VA, Merino MJ: Malignant mixed mullerian tumors of the uterus. An immunohistochemical study. Int J Gynecol Pathol 7:123–130, 1988
3. Azumi N, Ben-Ezra J, Battifora H: Immunophenotypic diagnosis of leiomyosarcomas and rhabdomyosarcomas with monoclonal antibodies to muscle-specific actin and desmin in formalin-fixed tissue. Mod Pathol 1:469–474, 1988
4. Bonazzi del Poggetto C, Virtanen I, Lehto VP, et al: Expression of intermediate filaments in ovarian and uterine tumors. Int J Gynecol Pathol 1:359–366, 1983
5. Borazja measur Gyneco
6. Brescia gonado of comp
7. Brisigot patholo 1989
8. Brown and sm
9. Carcang estroger noma. I
10. Chamb estroger noma. I and sur
11. Cintorir actin in Cancer
12. Costa M granulo Hum Pa
13. Czernob neoplas tumor d
14. Czernob SM acti neoplas
15. Dabbs D cervical 10:568–5
16. Dallenb Invasive 187:36–4
17. Darne J progest 38:216–2
18. Davies J (NDOG 78:899–9
19. Deaman a predi 1:188–19
20. Ehrman and type 72:257–2
21. Esquius neoplast cell carc
22. Farhood Pathol 2
23. Fleuren tumors.
24. Fowler I noembry primary 1994

5. Borazjani G, Twiggs LB, Leung BS, et al: Prognostic significance of steroid receptors measured in primary metastatic and recurrent endometrial carcinoma. Am J Obstet Gynecol 161:1253–1257, 1989
6. Brescia RJ, Kurman RJ, Main CS, et al: Immunocytochemical localization of chorionic gonadotropin, placental lactogen, and placental alkaline phosphatase in the diagnosis of complete and partial hydatidiform moles. Int J Gynecol Pathol 6:213–229, 1987
7. Brisigotti M, Moreno A, Murcia C, et al: Verrucous carcinoma of the vulva. A clinicopathologic and immunohistochemical study of five cases. Int J Gynecol Pathol 8:1–7, 1989
8. Brown DC, Theaker JM, Banks PM, et al: Cytokeratin expression in smooth muscle and smooth muscle tumors. Histopathol 11:477–486, 1987
9. Carcangiu MI, Chambers JT, Voynick IM, et al: Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol 94:247–254, 1990
10. Chambers JT, Carcangiu ML, Voynick IM, et al: Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 94:255–260, 1990
11. Cintorino M, Bellizzi de Marco E, Leoncini P, et al: Expression of alpha-smooth-muscle actin in stromal cells of the uterine cervix during epithelial neoplastic changes. Int J Cancer 47:843–846, 1991
12. Costa MJ, DeRose PB, Roth LM, et al: Immunohistochemical phenotype of ovarian granulosa cell tumors: Absence of epithelial membrane antigen has diagnostic value. Hum Pathol 25:60–66, 1994
13. Czernobilsky B, Moll R, Franke WW, et al: Intermediate filaments of normal and neoplastic tissues of the female genital tract with emphasis on problems of differential tumor diagnosis. Pathol Res Pract 179:31–57, 1984
14. Czernobilsky B, Shezen E, Lifschitz-Mercer B, et al: Alpha smooth muscle actin (alpha-SM actin) in normal human ovaries, in ovarian stromal hyperplasia and in ovarian neoplasms. Virchows Arch B Cell Pathol 57:55–61, 1989
15. Dabbs DJ, Geisinger KR, Norris HT: Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol 10:568–576, 1986
16. Dallenbach-Hellweg G, Lang G: Immunohistochemical studies on uterine tumors. I. Invasive squamous cell carcinomas of the cervix and their precursors. Pathol Res Pract 187:36–43, 1991
17. Darne J, Soutter WP, Ginsberg R, et al: Nuclear and "cytoplasmic" estrogen and progesterone receptors in squamous cell carcinoma of the cervix. Gynecol Oncol 38:216–219, 1990
18. Davies JO, Davies ER, Howe K, et al: Practical application of monoclonal antibody (NDOG2) against placental alkaline phosphatase in ovarian cancer. J Roy Soc Med 78:899–905, 1985
19. Deamant FD, Pombo MT, Battifora H: Estrogen receptor immunohistochemistry as a predictor of site of origin in metastatic breast cancer. Appl Immunohistochem 1:188–192, 1993
20. Ehrmann RL, Dwyer IM, Yavner D, et al: An immunohistochemical study of laminin and type IV collagen distribution in carcinoma of the cervix and vulva. Obstet Gynecol 72:257–262, 1988
21. Esquius J, Brisigotti M, Matias-Guiu X, et al: Keratin expression in normal vulva, non-neoplastic epithelial disorders, vulvar intraepithelial neoplasia, and invasive squamous cell carcinoma. Int J Gynecol Pathol 10:341–355, 1991
22. Farhood AI, Abrams J: Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol 22:224–230, 1991
23. Fleuren GJ, Nap M: Carcinoembryonic antigen in primary and metastatic ovarian tumors. Gynecol Oncol 30:407–415, 1988
24. Fowler LJ, Maygarden SJ, Novotny DB: Human alveolar macrophage-56 and carcinoembryonic antigen monoclonal antibodies in the differential diagnosis between primary ovarian and metastatic gastrointestinal carcinomas. Hum Pathol 25:666–670, 1994

25. Franquemont DW, Frierson HF Jr, Mills SE: An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol 15:861–870, 1991
26. Geisinger KR, Marshall RB, Kute TE, et al: Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 58:1506–1517, 1986
27. Gigi-Leitner O, Geiger B, Levy R, et al: Cytokeratin expression in squamous metaplasia of the human uterine cervix. Differentiation 31:191–205, 1986
28. Gown AM, Boyd HC, Chang Y, et al: Smooth muscle cells can express cytokeratins of "simple" epithelium. Immunocytochemical and biochemical studies in vitro and in vivo. Am J Pathol 132:223–232, 1988
29. Hammond RH, Bates TD, Clarke DG, et al: The immunoperoxidase localization of tumour markers in ovarian cancer: the value of CEA, EMA, cytokeratin and DD9. Br J Obstet Gynaecol 98:73–83, 1991
30. Harms D, Janig U: Germ cell tumors of childhood. Report of 170 cases including 59 pure and partial yolk-sac tumours. Virchows Arch A Pathol Anat Histopathol 409:223–239, 1986
31. Ishikura H, Scully RE: Hepatoid carcinoma of the ovary. A newly described tumor. Cancer 60:2775–2784, 1987
32. Ivanyi D, Ansink A, Groeneveld E, et al: New monoclonal antibodies recognizing epidermal differentiation-associated keratins in formalin-fixed, paraffin-embedded tissue. Keratin 10 expression in carcinoma of the vulva. J Pathol 159:7–12, 1989
33. Ivanyi D, Groeneveld E, Van Doornewaard G, et al: Keratin subtypes in carcinomas of the uterine cervix: Implications for histogenesis and differential diagnosis. Cancer Res 50:5143–5152, 1990
34. Khalifa MA, Sesterhenn IA: Tumor markers of epithelial ovarian neoplasms. Int J Gynecol Pathol 9:217–230, 1990
35. Khong TY, Lane EB, Robertson WB: An immunocytochemical study of fetal cells at the maternal-placental interface using monoclonal antibodies to keratins, vimentin and desmin. Cell Tissue Res 246:189–195, 1986
36. Kleine W, Maier T, Geyer H, et al: Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38:59–65, 1990
37. Konishi I, Fujii S, Kataoka N, et al: Ovarian mucinous cystadenocarcinoma producing alpha-fetoprotein. Int J Gynecol Pathol 7:182–189, 1988
38. Konishi I, Fujii S, Nonogaki H, et al: Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 68:1340–1350, 1991
39. Kurman RJ, Young RH, Norris HJ, et al: Immunocytochemical localization of placental lactogen and chorionic gonadotropin in the normal placenta and trophoblastic tumors, with emphasis on intermediate trophoblast and the placental site trophoblastic tumor. International Journal of Gynecol Pathol 3:101–121, 1984
40. Lifschitz-Mercer B, Czernobilsky B, Dgani R, et al: Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas. Cancer 59:1494–1499, 1987
41. Lifschitz-Mercer B, Czernobilsky B, Shezen E, et al: Selective expression of cytokeratin polypeptides in various epithelia of human Brenner tumor. Hum Pathol 19:640–650, 1988
42. Lin M, Hanai J, Wada A, et al: S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases. Acta Pathol Jpn 41:233–239, 1991
43. Lindgren J, Vesterinen E, Purola E, et al: Prognostic significance of tissue carcinoembryonic antigen in mild dysplasia of the uterine cervix. Tumor Biol 6:465–470, 1986
44. Martin JD, Hahnel R, McCartney AJ, et al: The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix. Gynecol Oncol 23:329–335, 1986
45. Matsukuma K, Tsukamoto N: Alpha-fetoprotein producing endometrial adenocarcinoma. Gynecol Oncol 29:370–377, 1988
46. McDicken IW, Rainey M: The immunohistological demonstration of carcinoembryonic antigen in
7:475–485,
47. McLaughl
in cervical
48. McNutt M
human ep
49. Miettinen
The comm
50. Miettinen
ovaries an
Pathol 2:64
51. Miettinen
cord-strom
proteins. A
52. Moll I, Mo
from those
53. Moll R, Fr
expression
54. Moll R, L
neoplasms
55. Moll R, Lo
nostic mar
56. Moll R, P
proteins, ir
Hum Path
57. Mosny DS,
receptors i
Oncol 35:3
58. Nagle RB,
keratins in
31:1010–10
59. Nagle RB,
extramamm
1985
60. Navarro D
estrogen re
hormone r
61. Neuntcufe
during the
Lett 48:77–
62. Norton AJ,
reactive w
biochemica
Histopatho
63. Puts J, Mo
filament p
Gynecol Pa
64. Raju GC: E
thol 12:437
65. Ramaekers
in the diffe
66. Ramaekers
the differen
19:347–353,
67. Ramaekers
by analysis
68. Runowicz
status in p

antigen in intra-epithelial and invasive squamous carcinoma of the cervix. Histopathol 7:475–485, 1983
47. McLaughlin PJ, Warne PH, Hutchinson GE, et al: Placental-type alkaline phosphatase in cervical neoplasia. Br J Cancer 55:197–201, 1987
48. McNutt MA, Bolen JW, Gown AM, et al: Coexpression of intermediate filaments in human epithelial neoplasms. Ultrastruct Pathol 9:31–43, 1985
49. Miettinen M, Franssila K: Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. Lab Invest 61:623–628, 1989
50. Miettinen M, Lehto VP, Virtanen I: Expression of intermediate filaments in normal ovaries and ovarian epithelial, sex cord-stromal, and germinal tumors. Int J Gynecol Pathol 2:64–71, 1983
51. Miettinen M, Wahlstrom T, Virtanen I, et al: Cellular differentiation in ovarian sex-cord-stromal and germ-cell tumors studied with antibodies to intermediate-filament proteins. Am J Surg Pathol 9:640–651, 1985
52. Moll I, Moll R: Cells of extramammary Paget's disease express cytokeratins different from those of epidermal cells. J Invest Dermatol 84:3–8, 1985
53. Moll R, Franke WW, Schiller DL, et al: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors, and cultured cells. Cell 31:11–24, 1982
54. Moll R, Levy R, Czernobilsky B, et al: Cytokeratins of normal epithelia and some neoplasms of the female genital tract. Lab Invest 49:599–610, 1983
55. Moll R, Lowe A, Laufer J, et al: Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 140:427–447, 1992
56. Moll R, Pitz S, Levy R, et al: Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas. Hum Pathol 22:989–1001, 1991
57. Mosny DS, Herholz J, Degen W, et al: Immunohistochemical investigations of steroid receptors in normal and neoplastic squamous epithelium of the uterine cervix. Gynecol Oncol 35:373–377, 1989
58. Nagle RB, Clark VA, McDaniel KM, et al: Immunohistochemical demonstration of keratins in human ovarian neoplasms. A comparative method. J Histochem Cytochem 31:1010–1014, 1983
59. Nagle RB, Lucas DO, McDaniel KM, et al: New evidence linking mammary and extramammary Paget cells to a common cell phenotype. Am J Clin Pathol 83:431–438, 1985
60. Navarro D, Cabrera JJ, Leon L, et al: Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. J Steroid Biochem Mol Biol 41:589–596, 1992
61. Neunteufel W, Breitenecker G: CA 19-9, CA 125 and CEA in the endometrial mucosa during the menstrual cycle, in atypical hyperplasia and endometrial carcinoma. Cancer Lett 48:77–83, 1989
62. Norton AJ, Thomas JA, Isaacson PG: Cytokeratin-specific monoclonal antibodies are reactive with tumours of smooth muscle derivation. An immunocytochemical and biochemical study using antibodies to intermediate filament cytoskeletal proteins. Histopathol 11:487–499, 1987
63. Puts J, Moesker O, Aldeweireldt J, et al: Application of antibodies to intermediate filament proteins in simple and complex tumors of the female genital tract. Int J Gynecol Pathol 6:257–274, 1987
64. Raju GC: Expression of the cytokeratin marker CAM 5.2 in cervical neoplasia. Histopathol 12:437–443, 1988
65. Ramaekers F, van Niekerk C, Poels L, et al: Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol 136:641–655, 1990
66. Ramaekers FC, Puts JJ, Kenemans P, et al: Use of intermediate filament antibodies in the differential diagnosis of gynecological neoplasia. Eur J Obstet Gynecol Reprod Biol 19:347–353, 1985
67. Ramaekers FC, Verheijen RH, Moesker O, et al: Mesodermal mixed tumor. Diagnosis by analysis of intermediate filament proteins. Am J Surg Pathol 7:381–385, 1983
68. Runowicz CD, Nuchtern LM, Braunstein JD, et al: Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecol Oncol 38:437–441, 1990

69. Scambia G, Panici PB, Baiocchi G, et al: Steroid hormone receptors in carcinoma of the cervix: Lack of response to an antiestrogen. Gynecol Oncol 37:323–326, 1990
70. Smedts F, Ramaekers F, Robben H, et al: Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol 136:657–668, 1990
71. Smedts F, Ramaekers F, Troyanovsky S, et al: Keratin expression in cervical cancer. Am J Pathol 141:497–511, 1992
72. Smedts F, Ramaekers F, Troyanovsky S, et al: Basal-cell keratins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am J Pathol 140:601–612, 1992
73. Szpak CA, Soper JT, Thor A, et al: Detection of adenocarcinoma in peritoneal washings by staining with monoclonal antibody B72.3. Acta Cytol 33:205–214, 1989
74. Thor A, Viglione MJ, Muraro R, et al: Monoclonal antibody B72.3 reactivity with human endometrium: A study of normal and malignant tissues. Int J Gynecol Pathol 6:235–247, 1987
75. Tosi P, Sforza V, Santopietro R: Estrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma. Obstet Gynecol 73:75–78, 1989
76. Ueda G, Yamasaki M: Neuroendocrine carcinoma of the uterus. Curr Topics Pathol 85:309–335, 1992
77. van Niekerk CC, Ramaekers FC, Hanselaar AG, et al: Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 142:157–177, 1993
78. Viale G, Gambacorta M, Dell'Orto P, et al: Coexpression of cytokeratins and vimentin in common epithelial tumors of the ovary: An immunocytochemical study of eighty-three cases. Virchows Arch A Pathol Anatomy Histopathol 413:91–101, 1988
79. Younes M, Katikaneni P, Lechago L, et al: HAM56 antibody: A tool in the differential diagnosis between colorectal and gynecological malignancy. Mod Pathol 7:396–400, 1994
80. Zirker TA, Silva EG, Morris M, et al: Immunohistochemical differentiation of clear-cell carcinoma of the female genital tract and endodermal sinus tumor with the use of alpha-fetoprotein and Leu-M1. Am J Clin Pathol 91:511–514, 1989

*Address reprint requests to*

Jay H. Beckstead, MD
Department of Pathology, L113
Oregon Health Sciences University
3181 SW Sam Jackson Park Road
Portland, OR 97201